Upstream Bio发布了Verekitug治疗重度哮喘的2期HARIANT试验的总体数据，满足年度哮喘加重率的主要终点

2026-02-11 19:04

Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.
Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens.
Verekitug was generally well tolerated, with a safety profile consistent with prior studies.
Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study.
Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions